Gene · 2230
Papers1,417
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,417
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy. | Int J Nanomedicine | 2026 | 41800437 | PubTator, text mining | PubMed |
| Copper-doped COF triggered bioorthogonal synergistic cancer therapy through apoptosis and cuproptosis. | Bioorg Chem | 2026 | 41795342 | PubTator, text mining | PubMed |
| Native chromatome profiling reveals hundreds of metabolic enzymes in the nucleus across tissues. | Nat Commun | 2026 | 41792114 | PubTator, text mining | PubMed |
| Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation. | Front Immunol | 2026 | 41789093 | PubTator, text mining | PubMed |
| Copper Homeostasis and Cuproptosis in Neurological Disorders. | Drug Des Devel Ther | 2026 | 41783572 | PubTator, text mining | PubMed |
| Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. | Mol Biomed | 2026 | 41772328 | PubTator, text mining | PubMed |
| Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications. | Front Pharmacol | 2026 | 41769686 | PubTator, text mining | PubMed |
| Sanguinarine exerts anti-hepatocellular carcinoma activity by targeting FDX1 to induce FDX1/LIAS/DLAT/HSP70 axis-dependent cuproptosis. | Acta Biochim Biophys Sin (Shanghai) | 2026 | 41764347 | PubTator, text mining | PubMed |
| Cuproptosis-related gene signatures define immune subtypes and predict prognosis in gastric cancer. | Front Mol Biosci | 2026 | 41737832 | PubTator, text mining | PubMed |
| AT-101 inhibits the proliferation and invasion of tongue squamous carcinoma cells by targeting the miR-21-5p/FDX1 axis. | Sci Rep | 2026 | 41735357 | PubTator, text mining | PubMed |
| Prophylactic self-assembled nucleic acid hydrogel targeting retinal ganglion cell cuproptosis and microglial neuroinflammation for retinal ischemia-reperfusion injury. | Bioact Mater | 2026 | 41727276 | PubTator, text mining | PubMed |
| Simultaneous Imaging of Cu+ and Cu2 + in Neural Cells Using DNAzyme Probes Reveals Mechanistic Link Between Copper Redox Imbalance and Amyloid Pathology. | Angew Chem Int Ed Engl | 2026 | 41721588 | PubTator, text mining | PubMed |
| Boosting Cuproptosis in Breast Cancer Therapy via Photodynamic Treatment With a New Liposome. | FASEB Bioadv | 2026 | 41716905 | PubTator, text mining | PubMed |
| Copper-based nanozymes synergistically enhance Cuproptosis for psoriasis treatment. | Mater Today Bio | 2026 | 41696156 | PubTator, text mining | PubMed |
| Cuproptosis: Biomarkers, Mechanisms and Treatments in Diseases. | Molecules | 2026 | 41683374 | PubTator, text mining | PubMed |
| Multi-Targeting Effects and Orchestrated Induction of Multiple Cell Death Modalities by Silver-Copper Alloy Nanoparticles Functionalized Drug Nanocrystals in Cancer Cells. | Mol Pharm | 2026 | 41674488 | PubTator, text mining | PubMed |
| Single-Cell Multiomics Decoding of TCIRG1-Mediated Cuproptosis Circuitry Rewiring Immune-Metabolic Landscape in Ischemic Stroke. | Transl Stroke Res | 2026 | 41673363 | PubTator, text mining | PubMed |
| PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction. | Oncogene | 2026 | 41673093 | PubTator, text mining | PubMed |
| Development and validation of a robust cuproptosis related signature for primary glioma via machine learning aided by loop training and validation. | Discov Oncol | 2026 | 41629670 | PubTator, text mining | PubMed |
| Integrated analysis and functional validation reveal KCNQ1 tumor suppressor targeting by dahuang Zhechong Pills via cuproptosis modulation in colorectal cancer. | Comput Biol Chem | 2026 | 41619690 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2230/papers?page=6